Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
featured
Published in COVID-19 and
1 other channel

Journal Scan / Research · July 17, 2022

Efficacy of BNT162b2 Vaccine Against SARS-CoV-2 Infection and Severe COVID-19 in Children Aged 5 to 11 Years

The Lancet

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Jonathan Temte MD, PhD

The Lancet
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022
Lancet 2022 Jul 09;400(10346)97-103, C Sacco, M Del Manso, A Mateo-Urdiales, MC Rota, D Petrone, F Riccardo, A Bella, A Siddu, S Battilomo, V Proietti, P Popoli, F Menniti Ippolito, AT Palamara, S Brusaferro, G Rezza, P Pezzotti, M Fabiani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated